Skip to main content
S&P 5007,758.16+1.41%DOW51,978.63+0.57%NASDAQ27,079.50+2.10%BTC$85,846.00+5.55%ETH$2,740.60+4.12%GOLD$4,377.20-1.08%OIL$92.03-4.22%
Smart Investors Daily
AN

NASDAQ · ANEB

Anebulo Pharmaceuticals, Inc.

Healthcare · Biotechnology

$0.32

Up+$0.02 (+5.00%)

Updated Sep 21, 2026, 5:53 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.68M
P/E ratio
-1.85
Dividend yield
0.00%
52-week range
— – —
Volume
100
Avg. volume
100.45K

Price performance

ANEB price history

1M range · 0 trading sessions · Daily adjusted prices

ANEB does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ANEB news

The latest Smart Investors Daily articles mentioning ANEB.

Stock researchCompany · Overview

ANEB research

Overview

Company profile and research snapshot.

Company profile

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
ANEB recent ratings
DateFirmRatingTarget
Jul 23, 2025Maxim GroupHold—
May 15, 2025Maxim GroupBuy—
Nov 19, 2024BenchmarkSpeculative Buy—
Oct 1, 2024BenchmarkSpeculative Buy—
Oct 3, 2023BenchmarkSpeculative Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

Cannabis Use Disorder Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035

The global cannabis use disorder market is projected to grow significantly from 2025 to 2035, driven by cannabis legalization, rising awareness, research funding and demand for effective addiction treatments. Investigational therapies include cannabinoid receptor modulators and serotonin-based drugs, such as Aelis Farma’s AEF0117 and Anebulo Pharmaceuticals’ ANEB-001. North America is expected to lead, followed by Europe, while Asia-Pacific and other regions offer emerging opportunities. Key bar

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By